CHIMERIC THERAPEUTICS LIMITED

*Disclaimer

CHIMERIC THERAPEUTICS LIMITED (ASX: CHM)

🔗 📄 📈

CHM: Launch of new Phase 1B Glioblastoma clinical trial

CHIMERIC THERAPEUTICS LIMITED

Chimeric Therapeutics announces the launch of a new Phase 1B clinical trial for CHM 1101 (CLXT CAR T) in patients with recurrent and/or progressive glioblastoma multiforme (GBM).
The trial is now open for enrollment at the Sarah Cannon Transplant & Cellular Therapy Program at St. David's South Austin Medical Center in Austin, Texas.
The Phase 1B trial aims to determine a recommended Phase 2 dose and administration schedule, with plans to design and initiate a registration trial upon successful completion.

2023-06-05 08:54:00

CHM: BOARD & MANAGEMENT COMMIT TO $1M PLACEMENT AND PROPOSED SPP

CHIMERIC THERAPEUTICS LIMITED

Chimeric Therapeutics board and management commit to a $1.04m placement at $0.046 per share, equal to the last close price on 12 May 2023.
The company also intends to launch a share purchase plan to raise up to $5.25m, providing eligible shareholders the opportunity to participate in the capital raising on more favorable terms.
The funds raised will be used for the continued development of Chimeric's world-class portfolio of cell therapy technologies.

2023-05-15 09:40:00

CHM: New CLTX CAR technology patent protection in India & Israel

CHIMERIC THERAPEUTICS LIMITED

Chimeric Therapeutics has been granted patent IN 424963 in India for applications of CAR technology using chlorotoxin, including assets CHM 1101 and CHM 1301.
Israel Patent Office has issued a notice of allowance for application IL 258670.
Chimeric holds the exclusive worldwide license to develop and commercialize these patents and related applications in other global territories.

2023-04-28 09:44:00

CHM: Phase 1B brain cancer clinical trial approved for initiation

CHIMERIC THERAPEUTICS LIMITED

Chimeric Therapeutics has received ethics approval for a multi-site Phase 1B clinical trial of CHM 1101 in patients with recurrent and/or progressive glioblastoma multiforme (GBM).
The trial will consist of two parts, with Part A involving 3-6 patients and focusing on dose escalation, and Part B enrolling 12-26 patients to assess efficacy and safety using the recommended Phase 2 dosing plan.
A registration trial will be initiated following the successful completion of Part B and in alignment with regulatory feedback.

2023-04-26 08:47:00

CHM: CHM 1101 GBM Abstract Accepted for ASCO 2023 Presentation

CHIMERIC THERAPEUTICS LIMITED

CHM 1101 abstract has been accepted for presentation at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO).
The abstract focuses on the clinical trial design and objectives for the new Phase 1B CHM 1101 clinical trial.
CHM 1101 (CLTX CAR T) is a potentially groundbreaking CAR T therapy for patients with recurrent or progressive glioblastoma.

2023-04-03 14:15:00

CHM: Positive pre-IND meeting with FDA for Phase 1 CAR T study

CHIMERIC THERAPEUTICS LIMITED

Chimeric Therapeutics receives positive feedback and guidance from the FDA for their proposed Phase 1 clinical trial using CHM 2101 for gastrointestinal and neuroendocrine tumors.
This is a significant milestone for Chimeric's development pathway as the FDA's input supports their technical operations strategy.
The feedback aligns with Chimeric's development plan and brings them closer to potentially transforming the lives of patients with these types of tumors.

2023-03-21 09:55:00

CHM: Fourth dose cohort initiated in CHM 1101 Phase 1 trial

CHIMERIC THERAPEUTICS LIMITED

The first patient in the fourth dose cohort of the CHM 1101 (CLTX CAR T cell) clinical trial at City of Hope has received dosing.
Patients in this dose level will receive a total dose of 440 X 106 CHM 1101 (CLTX CAR T cells) through dual routes of intratumoral and intraventricular administration.
Chimeric Therapeutics is pleased to announce the initiation of treatment of the first patient in the fourth dose cohort at City of Hope's phase 1 clinical trial.

2023-03-02 12:30:00

CHM: Follow up period completed for 3rd cohort in CHM 1101 trial

CHIMERIC THERAPEUTICS LIMITED

The 3rd dose cohort in the CHM 1101 (CLTX CAR T) cell therapy phase 1 clinical trial was completed without any dose limiting toxicities.
The 3rd dose cohort treated patients at a total dose of 240 X 106 CHM 1101 (CLTX CAR T) cells through dual routes of administration.
The phase 1 clinical trial will now advance to the 4th and final dose cohort with dual routes of administration at a total dose of 440 X 106 CHM 1101 (CLTX CAR T) cells.

2023-01-23 08:45:00

ASX Briefs...everything...in 3 bullet points

ASX Briefs

*Disclaimer

CHIMERIC THERAPEUTICS LIMITED (ASX: CHM)

CHM: Launch of new Phase 1B Glioblastoma clinical trial

CHIMERIC THERAPEUTICS LIMITED

CHM: BOARD & MANAGEMENT COMMIT TO $1M PLACEMENT AND PROPOSED SPP

CHIMERIC THERAPEUTICS LIMITED

CHM: New CLTX CAR technology patent protection in India & Israel

CHIMERIC THERAPEUTICS LIMITED

CHM: Phase 1B brain cancer clinical trial approved for initiation

CHIMERIC THERAPEUTICS LIMITED

CHM: CHM 1101 GBM Abstract Accepted for ASCO 2023 Presentation

CHIMERIC THERAPEUTICS LIMITED

CHM: Positive pre-IND meeting with FDA for Phase 1 CAR T study

CHIMERIC THERAPEUTICS LIMITED

CHM: Fourth dose cohort initiated in CHM 1101 Phase 1 trial

CHIMERIC THERAPEUTICS LIMITED

CHM: Follow up period completed for 3rd cohort in CHM 1101 trial

CHIMERIC THERAPEUTICS LIMITED